Ker Yu

5.5k citations

84 papers · 4.5k indexed · 1 hit paper · h-index 36

Molecular Biology top 2%
- PI3K/AKT/mTOR signaling in cancer 45
- Protein Kinase Regulation and GTPase Signaling 12
Cancer Research top 5%
Organic Chemistry top 2%
- Synthesis and biological activity 5
- Quinazolinone synthesis and applications 5
Toxicology top 2%
Genetics top 5%
Oncology
- Cancer Immunotherapy and Biomarkers 8
Ecology, Evolution, Behavior and Systematics
- Fungal Plant Pathogen Control 6
Immunology
- Mast cells and histamine 6
Pharmacology
- Microbial Natural Products and Biosynthesis 5

Co-authors: Robert T. Abraham Lourdes Toral‐Barza James J. Gibbons Judy Lucas Arie Zask Boris Shor Semiramis Ayral‐Kaloustian Irwin Hollander
Cited by: Molecular Biology Cancer Research Organic Chemistry
Journals: Bioorganic & Medicinal Chemistry Letters (14 papers)Journal of Medicinal Chemistry (11 papers)Acta Pharmacologica Sinica (5 papers)
Partner nations: United States China Canada

In The Last Decade

Ker Yu

83 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Ker Yu

Since Specialization

Citations

This map shows the geographic impact of Ker Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ker Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ker Yu more than expected).

Fields of papers citing papers by Ker Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ker Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ker Yu. The network helps show where Ker Yu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ker Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ker Yu Line = papers co-authored together Ker Yu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	SMS2 siRNA inhibits pancreatic tumor growth by tumor microenvironment modulation International Immunopharmacology ·Xin Jiang,Nam Cheong-Soo,Tingbo Ding,Ker Yu,Jibin Dong	2024	1
2	Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma Oncogene ·Jim McMartin,Jean Macq,Zhiqiang Ren,Ker Yu	2024	5
3	Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function Cancer Letters ·Zhiqiang Ren,Jim McMartin,Liang Liu,Xuesai Zhang,شهاب الدین صافی,Christina M. Bauer,Yue Wang,Ker Yu	2023	17
4	RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers Journal of Experimental & Clinical Cancer Research ·Li Xia,Harold V. M. van Rijen,J. Z. Zhang,Chenglong Liu,Lian Shen,Yafei Huang,Martin Kutscha,Jinlong Tian,Ker Yu,Yonghui Wang,Qiong Xie,Di Zhu	2022	33
5	BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer Signal Transduction and Targeted Therapy ·Mei Feng,Martin Kutscha,Yan Zhou,K. Miyo,Harold V. M. van Rijen,Shenglin Mei,Yuanyuan Zhu,Chenglong Liu,F. R. Jevons,Huiyu Li,Cao Xie,Joy Q. Jin,Jibin Dong,Dehua Yang,Ker Yu,Jun Qian,Diether Lambrechts,Ming‐Wei Wang,Di Zhu	2021	28
6	Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function Molecular Cancer Therapeutics ·Rui Jin,Liang Liu,Yun Xing,Tao Meng,Lanping Ma,شهاب الدین صافی,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu	2020	21
7	Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer Acta Pharmacologica Sinica ·Yan Deng,منذر فخري الشناق,Shuhua He,Bin Lou,Tingbo Ding,Jintong Yang,Züleyha PESTIL¹,Carlos Gerardo Quispe Reynoso,Lu Zhou,Xian‐Cheng Jiang,Ker Yu,Jibin Dong	2020	39
8	A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer Clinical Cancer Research ·Qianwen Zhang,Yan Zhang,Yaqing Chen,Jianchang Qian,Xuesai Zhang,Ker Yu	2019	51
9	Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers Acta Pharmacologica Sinica ·K. Polkinghorne,Hui Zhao,Xuesai Zhang,Martin Greve,Ker Yu	2018	30
10	Identification of pyrimidine derivatives as hSMG-1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Ariamala Gopalsamy,Eric M. Bennett,Mengxiao Shi,Weiguo Zhang,Joel Bard,Ker Yu	2012	44
11	Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2 Cancer Research ·Ker Yu,Celine Shi,Lourdes Toral‐Barza,Judy Lucas,Boris Shor,H. J. Trodahl,Weiguo Zhang,Robert Mahoney,Maurousset Laurence,G. Álvarez-Carreto,Resta Andriana Putri,Singh Prabhjot,Kevin J. Curran,Joshua A. Kaplan,Jeroen C. Verheijen,Semiramis Ayral‐Kaloustian,Tarek S. Mansour,Robert T. Abraham,Arie Zask,James J. Gibbons	2010	162
12	2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability Bioorganic & Medicinal Chemistry Letters ·Jeroen C. Verheijen,David J. Richard,Kevin J. Curran,Joshua A. Kaplan,Ker Yu,Arie Zask	2010	22
13	4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR) Bioorganic & Medicinal Chemistry Letters ·Hwei‐Ru Tsou,Jared Ray McCoppin,Gary H. Birnberg,Nan Zhang,Natasja Brooijmans,Lourdes Toral‐Barza,Irwin Hollander,Semiramis Ayral‐Kaloustian,Ker Yu	2010	19
14	Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin Cancer Research ·Ker Yu,Lourdes Toral‐Barza,Celine Shi,Weiguo Zhang,Judy Lucas,Boris Shor,P. Kolle,Jeroen C. Verheijen,Kevin J. Curran,David J. Malwitz,Derek C. Cole,John W. Ellingboe,Semiramis Ayral‐Kaloustian,Tarek S. Mansour,James J. Gibbons,Robert T. Abraham,Paweł Nowak,Arie Zask	2009	277
15	Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K Bioorganic & Medicinal Chemistry Letters ·Jeroen C. Verheijen,Ker Yu,Lourdes Toral‐Barza,Irwin Hollander,Arie Zask	2009	32
16	Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability Bioorganic & Medicinal Chemistry Letters ·David J. Richard,Jeroen C. Verheijen,Kevin J. Curran,Joshua A. Kaplan,Lourdes Toral‐Barza,Irwin Hollander,Judy Lucas,Ker Yu,Arie Zask	2009	42
17	A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis Cancer Research ·Boris Shor,Weiguo Zhang,Lourdes Toral‐Barza,Jessica Lucas,Robert T. Abraham,James J. Gibbons,Ker Yu	2008	102
18	Characterization of the cloned full-length and a truncated human target of rapamycin: Activity, specificity, and enzyme inhibition as studied by a high capacity assay Biochemical and Biophysical Research Communications ·Lourdes Toral‐Barza,Weiguo Zhang,Du Sik Kim,James LaRocque,James J. Gibbons,Ker Yu	2005	33
19	Isolation, Structure Determination and Biological Activity of 15-Deoxo-7,32-O-didesmethylrapamycin from the Soil Actinomycete LL-D45042 The Journal of Antibiotics ·Edmund I. Graziani,Jacek Wiesiolowski,Jeffrey E. Janso,Ker Yu,Valerie S. Bernan,Michael Greenstein,Guy T. Carter	2004	0
20	Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoidsbreakdown → Journal of Biological Chemistry ·Ker Yu,William Bayona,Caleb B. Kallen,Heather P. Harding,Christina Ravera,Gerald McMahon,Myles Brown,Mitchell A. Lazar	1995	598

About Ker Yu

Ker Yu is a scholar working on Molecular Biology, Immunology, Toxicology, Organic Chemistry and Oncology, having authored 84 papers that have together received 4.5k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (45 papers), Protein Kinase Regulation and GTPase Signaling (12 papers), Cancer Immunotherapy and Biomarkers (8 papers), Fungal Plant Pathogen Control (6 papers), Mast cells and histamine (6 papers), Synthesis and biological activity (5 papers), Microbial Natural Products and Biosynthesis (5 papers) and Quinazolinone synthesis and applications (5 papers). The work is most often cited by research in Molecular Biology (3.3k citations), Cancer Research (570 citations), Organic Chemistry (800 citations), Toxicology (93 citations) and Genetics (275 citations). Ker Yu has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Robert T. Abraham, Lourdes Toral‐Barza, James J. Gibbons, Judy Lucas, Arie Zask, Boris Shor, Semiramis Ayral‐Kaloustian, Irwin Hollander, Jeroen C. Verheijen and Christina Ravera. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Acta Pharmacologica Sinica, Cancer Biology & Therapy and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact